Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based RegimenCompleted
NCT03279289Phase 2Updated Apr 13, 2023
Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Colorectal Cancer
Spain
Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United StatesCompleted
NCT05040802N/AUpdated Apr 13, 2023
Sponsor: Sanofi Pasteur, a Sanofi Company
Pertussis (Whooping Cough)
France
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseWithdrawn
NCT04143958Phase 4Updated Apr 7, 2023
Sponsor: Sanofi
Fabry Disease
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraCompleted
NCT02553317Phase 3Updated Apr 5, 2023
Sponsor: Ablynx, a Sanofi company
Acquired Thrombotic Thrombocytopenic Purpura
United States, Australia, Austria, Belgium, Canada +11 more
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)Completed
NCT05797701Phase 1Updated Apr 4, 2023
Sponsor: Sanofi
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
United States
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)Completed
NCT01151423Phase 2Updated Apr 4, 2023
Sponsor: Ablynx, a Sanofi company
Acquired Thrombotic Thrombocytopenic Purpura
United States, Australia, Austria, Belgium, Bulgaria +8 more
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) PatientsCompleted
NCT01020383Phase 2Updated Apr 4, 2023
Sponsor: Ablynx, a Sanofi company
Unstable Angina · Non ST Segment Elevation Myocardial Infarction (NSTEMI) · Stable Angina (Associated With High Risk PCI)
Austria, Belgium, Czechia, Germany, Israel +2 more
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant TreatmentCompleted
NCT00121992Phase 3Updated Apr 4, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Neoplasms
Spain
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult ParticipantsCompleted
NCT05795907Phase 1Updated Apr 3, 2023
Sponsor: Sanofi
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
United States
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast CancerCompleted
NCT00129935Phase 3Updated Mar 31, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple MyelomaCompleted
NCT03200626N/AUpdated Mar 28, 2023
Sponsor: Medical College of Wisconsin
Multiple Myeloma · Bone Marrow Transplant Complications
United States
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22Completed
NCT05078060N/AUpdated Mar 24, 2023
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
Finland, Germany
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.Completed
NCT01898364Phase 1Updated Mar 23, 2023
Sponsor: Genzyme, a Sanofi Company
Pompe Disease · Glycogen Storage Disease Type II (GSD II) · Acid Maltase Deficiency
United States, Belgium, Denmark, France, Germany +2 more
Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated SyndromeCompleted
NCT03122652Phase 3Updated Mar 17, 2023
Sponsor: Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
France, Switzerland, Turkey (Türkiye)
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)Completed
NCT03620747Phase 3Updated Mar 16, 2023
Sponsor: Sanofi
Asthma
United States, Argentina, Belgium, Canada, France +5 more
Recombinant Influenza Vaccination in U.S. Nursing HomesUnknown
NCT03965195Phase 4Updated Mar 15, 2023
Sponsor: Insight Therapeutics, LLC
Influenza · Influenza -Like Illness · Influenza, Human
United States
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompleted
NCT00644189Phase 1, Phase 2Updated Mar 15, 2023
Sponsor: Massachusetts General Hospital
Follicular Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma · Small Lymphocytic Lymphoma
United States
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult ParticipantsCompleted
NCT03122223Phase 1, Phase 2Updated Mar 14, 2023
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
United States, Tanzania, Zambia, Zimbabwe
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer PatientsCompleted
NCT00129896Phase 1, Phase 2Updated Mar 6, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
TAC Versus TC for Adjuvant Breast CancerCompleted
NCT00493870Phase 3Updated Mar 2, 2023
Sponsor: US Oncology Research
Breast Cancer
United States
French National Cohort of People With Type 1 DiabetesRecruiting
NCT04657783N/AUpdated Feb 15, 2023
Sponsor: Fondation Francophone pour la Recherche sur le Diabete
Diabetes Mellitus, Type 1 · Cardiovascular Diseases · Hypoglycemia · Patient Participation
France
A Study of PRN1008 in Adult Patients With Pemphigus VulgarisCompleted
NCT02704429Phase 2Updated Feb 13, 2023
Sponsor: Principia Biopharma, a Sanofi Company
Pemphigus Vulgaris
Australia, Croatia, France, Greece, Israel
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompleted
NCT03203642Phase 2Updated Feb 6, 2023
Sponsor: Kadmon, a Sanofi Company
Autosomal Dominant Polycystic Kidney · ADPKD
United States
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisCompleted
NCT03549871Phase 3Updated Feb 6, 2023
Sponsor: Genzyme, a Sanofi Company
Hemophilia
United States, Australia, China, Denmark, France +10 more
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal CancerCompleted
NCT03043729Phase 2Updated Feb 6, 2023
Sponsor: AIO-Studien-gGmbH
Rectal Cancer · Rectosigmoid Cancer
Germany

Previous page Next page